Track market-moving stories before they get noisy

         COMMUNIQUE DE PRESSE

AB SCIENCE PRÉSENTE SES RÉSULTATS FINANCIERS ANNUELS AU 31 DECEMBRE 2025 ET LES EVENEMENTS CLEFS DE LA PERIODE

Situation financière et corporate Déficit opérationnel de 3,8 millions d’euros au 31 décembre 2025 en baisse de 38% par rapport à l’exercice 2025 (hors événement non-courant)Trésorerie de 10,2 millions d’euros au 31 décembre 2025, à laquelle s’ajoute 3,2 millions d’euros au titre du placement privé réalisé en avril 2026Accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble des créanciers financiers Développement clinique : concentration des ressources sur la phase 3 du masitinib dans la SLA et la phase 1 d’AB8939 dans la leucémie myéloïde aiguë (LMA) Paris, 13 mai 2025, 19h

AB Science SA (Euronext - FR0010557264 - AB) annonce aujourd’hui ses résultats financiers annuels au 31 décembre 2025 et présente un point sur ses activités.

ÉVENEMENTS CLES RELATIFS AU DEVELOPPEMENT CLINIQUE AU COURS DE L’ANNEE 2025 ET DEPUIS LE 31 DECEMBRE 2025

Dans la sclérose latérale amyotrophique (SLA), le programme de développement du masitinib a franchi plusieurs étapes structurantes au cours des années 2025 et 2026 i)    Autorisation par plusieurs pays européens d'initier l'étude confirmatoire de phase 3

AB Science a annoncé en juillet 2025 annonce que l’étude confirmatoire de phase 3 avec le masitinib dans la sclérose latérale amyotrophique (SLA) (étude AB23005) a été autorisée par une première série de pays européens (Espagne, Grèce, Slovénie) dans l’étape 2 du Clinical Trials Information System, CTIS. Cette autorisation fait suite à la validation par l'EMA du protocole harmonisé approuvé à l’issue de la Phase 1 du CTIS ainsi qu’à l’autorisation reçue de la part de la FDA. Elle met à présent AB Science dans la possibilité d’initier cette étude d’enregistrement, en Europe et aux Etats Unis.

L'étude AB23005 est une étude de phase 3 prospective, multicentrique, randomisée, en double aveugle, contrôlée par placebo, en 2 groupes parallèles, visant à confirmer l'efficacité et la tolérance du masitinib (à la dose de 4.5 mg/kg/jour en association avec le riluzole) par rapport au riluzole associé à un placebo après 48 semaines de traitement dans la sclérose latérale amyotrophique.

L'étude doit inclure 408 patients (randomisation 1:1) atteints de SLA, ayant une vitesse de progression de la maladie dite normale (i.e. déclin du score fonctionnel inférieur à 1.1 points par mois) et n’ayant encore aucune perte totale de fonction (i.e. score de au moins 1 sur chacun des 12 items du score ALSFRS-R). Les patients américains recevant l’Edaravone pourront également participer à l’étude, la prise de ce médicament étant un facteur de stratification.

Ce design a fait l’objet d’une validation lors des interactions avec les autorités de santé européennes, notamment sur les critères de la population optimale choisie pour l’étude confirmatoire :

Patients sans progression rapide : Les experts du groupe consultatif scientifique neurologie (SAG-N) de l’EMA ont considéré la catégorisation de la population de l'étude avec les progresseurs normaux, en utilisant un taux moyen de changement de l'ALSFRS-R inférieur à 1,1 points par mois comme seuil, comme cliniquement pertinente et conforme à l'évolution attendue de la maladie, et donc acceptable dès lors qu’elle est prédéfinie, ce qui est le cas pour cette étude.Patients sans perte complète de fonction : Les experts du SAG-N ont estimé que l'échelle ALSFRS-R est largement utilisée dans la pratique clinique et que des critères d'administration sont disponibles pour les professionnels de santé. Par conséquent, le sous-groupe des patients atteints de SLA très sévère (qui ont un score de zéro sur au moins un des 12 items individuels de l'ALSFRS-R) peut être facilement identifiable dans la pratique clinique. Dans ce sous-groupe défini comme les patients avant toute perte complète de fonction et avec une progression normale de la maladie (DFS<1,1), qui correspond à la population optimale des meilleurs répondeurs au masitinib et devant être inclue dans l'étude AB23005, l'étude AB10015 a généré des résultats extrêmement solides, avec une augmentation de la médiane de survie de +12 mois.

Cette population optimale représente environ 75% de la population totale des patients atteints.

La population optimale représentait environ 90 patients par groupe de traitement dans l’étude AB10015. L’effet du masitinib était statistiquement significatif (p=0.0290) sur le critère CAFS qui est le critère reconnu par la FDA.

L’étude AB23005 recrutera environ 200 patients par groupe de traitement, soit plus du double, afin de viser une puissance statistique forte pour ce test et maximiser les chances de succès statistique.

ii)    Publication mettant en évidence le bénéfice clinique du masitinib

AB Science a annoncé en décembre 2025 la publication d'un nouvel article sur la plateforme de prépublication MedRxiv, présentant une analyse post-hoc de sous-groupes de l'étude de phase 2b/3 AB10015 évaluant le masitinib chez des patients atteints de sclérose latérale amyotrophique avant toute perte complète de fonction. Cet article, intitulé ‘Efficacy and safety of masitinib in amyotrophic lateral sclerosis patients prior to loss of functionality: a subgroup analysis optimizing the benefit-risk profile of masitinib’.

Dans cette population, les analyses présentées montrent :

Une amélioration significative du déclin fonctionnel mesuré par le score ALSFRS-R, avec une différence de 4,04 points en faveur du masitinib par rapport au placebo (p=0,0065)Un bénéfice significatif sur le CAFS (bénéfice relatif +20,2 %, p=0,0290)Une survie médiane sans progression (PFS) prolongée de 9 mois (p=0,0057)Une survie médiane globale (OS) augmentée de 12 mois (p=0,0192) Ces résultats ont été pris en compte dans le design de l'étude confirmatoire AB23005, qui cible une population optimisant le rapport bénéfice/risque afin d'augmenter les chances de succès de l'étude.

iii)    Identification d'un biomarqueur potentiel de l'activité du masitinib sur la microglie

AB Science a annoncé en février 2026 l'identification d'un biomarqueur potentiel pour évaluer l'activité du masitinib dans l'implication pathologique de la microglie dans la sclérose latérale amyotrophique.

Les principales caractéristiques de ce biomarqueur nouvellement identifié sont les suivantes :

Il s'agit d'un biomarqueur sanguin (plasmatique), qui présente l'avantage d'être facile à prélever et d'être évalué avec précision par ELISA (dosage immuno-enzymatique).Il est produit par la microglie pro-inflammatoire.Il active la microglie et les astrocytes et constitue donc un activateur contribuant à une boucle de rétroaction néfaste de la neuroinflammation.Il est également libéré par les mastocytes, établissant ainsi un lien entre les mastocytes et la microglie, qui sont les deux principales cibles cellulaires du masitinib.Il permet de prédire la survie dans la SLA, ce qui pourrait expliquer pourquoi le masitinib pourrait prolonger la survie chez certains patients spécifiques.Des expériences internes ont montré que ce biomarqueur était réduit par le masitinib lorsque les mastocytes et la microglie étaient activés in vitro, soulignant l'activité spécifique et puissante du masitinib sur les mastocytes et la microglie. iv)    Offre ferme d'assurance de financement d'essai clinique (CTFI)

AB Science a annoncé en février 2026 avoir reçu une offre ferme de souscription d'une police d'assurance de financement d'essai clinique de la part de Medical & Commercial International Ltd. (MCI), Lloyd's Syndicate 1902, pour son essai pivot de phase III AB23005 évaluant le masitinib (AB1010) en combinaison avec le traitement de référence dans la sclérose latérale amyotrophique (SLA). Le placement a été organisé par Acrisure Re UK, en collaboration avec sa filiale Acrisure Re Netherlands. La police offre une couverture sans franchise, avec une limite de responsabilité de 25 M€ pouvant atteindre 39 M€, destinée à couvrir l'intégralité des coûts financiers liés à un échec clinique. Elle prend effet à la date d'inclusion du premier patient, sous réserve de la mobilisation par AB Science du financement nécessaire à l'étude et au paiement de la prime d’un montant approximatif de 8 millions d’euros (montant incluant la prime d’assurance, les taxes, et les frais d’intermédiation, pour une limite de responsabilité de 25 M€, cette prime pouvant s’élever à un montant d’environ 13M€ pour une limite de responsabilité de 39 M€). L'offre est activable jusqu'au 31 décembre 2026.

Les cas couverts incluent un échec d'efficacité selon les critères FDA/EMA, un échec en matière de sécurité, un échec de recrutement, une suspension réglementaire, une violation des BPC ou de l'intégrité des données, un arrêt prématuré recommandé par le comité indépendant, ainsi que des problèmes de fabrication (CMC).

Cette structure constitue une réduction significative du profil de risque du programme SLA et de la Société, avec trois bénéfices pour les actionnaires : (i) protection du capital investi à hauteur de 25 M€ en cas d'échec ; (ii) validation externe de la conception de l'essai et du parcours réglementaire au travers de la diligence indépendante conduite par l'assureur ; (iii) amélioration de l'efficacité du capital et des conditions d'accès aux financements par dette et en fonds propres.

AB Science a continué à renforcer la propriété intellectuelle du masitinib dans les formes progressives de la sclérose en plaques, la drépanocytose et le cancer de la prostate AB Science a annoncé en janvier 2026 que l'Office japonais des brevets a officiellement délivré un brevet pour les méthodes de traitement de la sclérose en plaques (SEP) progressive avec sa molécule phare, le masitinib. Ce nouveau brevet (JP 7788154) garantit la protection de la propriété intellectuelle du masitinib jusqu'en février 2041. Il s'agit du premier pays à délivrer un brevet protégeant l'utilisation du masitinib dans les formes progressives de la SEP. AB Science a suivi pour la protection du masitinib dans les formes progressives de la SEP la même méthodologie que pour l'utilisation du masitinib dans la SLA. Ce dernier brevet a été accordé partout dans le monde. AB Science est optimiste quant à ses chances d'obtenir la protection de l'utilisation du masitinib dans la SEP progressive à l'échelle mondiale.

AB Science a annoncé en avril 2025 que l'Office des brevets des Etats-Unis a délivré un avis d'acceptation pour un brevet portant sur des méthodes (c'est-à-dire un brevet d'utilisation médicale) de traitement de la drépanocytose avec sa principale molécule, le masitinib, sur la base de résultats précliniques. Ce nouveau brevet américain protège jusqu'en novembre 2040 la propriété intellectuelle du masitinib dans cette indication et renforce encore la propriété intellectuelle du masitinib, après un avis d'acceptation reçu de l'Office européen des brevets en octobre 2024 pour le même brevet.

AB Science a annoncé en janvier 2026 que l'Office américain des brevets et des marques (USPTO) a délivré une notification d'acceptation (NOA) pour un brevet relatif aux méthodes de traitement du cancer de la prostate métastatique hormono-résistant (mCRPC) avec sa molécule phare, le masitinib (US 18/040884). Une fois délivré, ce nouveau brevet américain d'utilisation médicale secondaire assurera la protection de la propriété intellectuelle (PI) du masitinib dans le mCRPC jusqu'en mai 2042. Une NOA signifie que l'USPTO a l'intention d'accorder la demande de brevet après avoir accompli certaines formalités procédurales. La NOA américaine est délivrée après qu'un examinateur a confirmé que la demande de brevet répond à toutes les exigences en matière de brevetabilité. Ce nouveau brevet américain s'ajoute à la couverture déjà accordée en Europe (EP4175639). Des demandes de brevet équivalentes ont également été déposées dans d'autres grands marchés internationaux.

L’étude confirmatoire de phase 3 dans le cancer de la prostate métastatique hormono-résistant a été autorisée par la FDA et par l’EMA AB Science a annoncé en juillet 2025 qu'une étude confirmatoire de phase 3 avec le masitinib dans le cancer de la prostate métastatique hormono-résistant (étude AB22007) a été autorisée par la FDA et l'EMA (protocole harmonisé approuvé à l’issue de la Phase 1 du Clinical Trials Information System, CTIS), avec un biomarqueur qui cible les patients dont la maladie métastatique est moins avancée.

L'étude AB22007 est une étude de phase 3 prospective, multicentrique, randomisée, en double aveugle, contrôlée par placebo, en 2 groupes parallèles, visant à confirmer l'efficacité et la tolérance du docétaxel (injecté en intraveineuse à la dose de 75 mg/m² et associé à la prednisone jusqu’à 10 cycles) associé au masitinib à la dose de 6,0 mg/kg/j, par rapport au docétaxel associé à un placebo dans le cancer de la prostate métastatique hormono-résistant (mCRPC).

Le programme de développement d’AB8939 a également franchi plusieurs étapes structurantes au cours des années 2025 et 2026 i)    Autorisation en Europe de la troisième des quatre étapes de l’étude de Phase 1/2 dans la leucémie myéloïde aiguë (LMA) en rechute/réfractaire

AB Science a annoncé en juillet 2025 l’autorisation de la troisième des quatre étapes de l’étude de phase 1/2 (AB18001) avec la molécule AB8939 chez les patients adultes atteints de leucémie myéloïde aiguë (LMA) en rechute/réfractaire.

La troisième étape de l’étude a été autorisée en France, Allemagne, Espagne et Grèce.

L'objectif de l’étude de Phase 1 est de déterminer la dose maximale tolérée (DMT) pour différentes étapes de traitement d'AB8939.

Étape 1 : Détermination de la dose maximale tolérée (DMT) après 3 jours consécutifs de traitement avec AB8939 seul. Étape 2 : Détermination de la DMT après 14 jours consécutifs de traitement avec AB8939 seul. Étape 3 : Détermination de la DMT après 14 jours consécutifs de traitement avec AB8939 en combinaison avec le venetoclax. Étape 4 : Détermination de la DMT après 14 jours consécutifs de traitement avec AB8939 en combinaison avec le venetoclax et l'azacitidine. Les deux premières étapes de la phase 1 ont été terminées avec respectivement 28 patients et 13 inclus, et ont permis de déterminer la DMT d’AB8939 après 3 jours consécutifs de traitement (21.3 mg/m2) et après 14 jours consécutifs de traitement (21.3 mg/m2).

La troisième étape consiste à présent à évaluer la dose maximale tolérée après 14 jours consécutifs de traitement par AB8939 en association avec le venetoclax, un traitement de référence dans la LMA.

La combinaison AB8939 + venetoclax présente plusieurs intérêts potentiels :

Les deux molécules sont peu toxiques sur le plan hématologique. Cette combinaison pourrait donc représenter une combinaison moins toxique que azacitidine + venetoclax en première ligne de la LMA.Ces deux molécules agissent sur des cibles différentes et complémentaires dans les cellules cancéreuses, ce qui pourrait avoir un effet additif, voire synergique sur le plan de l’efficacité. Les traitements dans la LMA représentent un potentiel de marché estimé à plus de 2 milliards d’euros par an.

ii)    Annonce de la quatrième réponse consécutive avec la combinaison AB8939 + vénétoclax

AB Science a annoncé en janvier 2026 la quatrième réponse consécutive avec la combinaison AB8939 + vénétoclax des patients atteints de leucémie myéloïde aiguë (LMA) associée à un profil génétique très défavorable.

Le traitement combiné a été bien toléré, sans toxicité hématologique ni toxicité limitant la dose Le quatrième patient présentait un caryotype complexe comprenant une monosomie du chromosome 5 et une mutation TP53, et était en troisième ligne de traitement. Il a obtenu une réponse presque complète après 14 jours de traitement par AB8939 à 21 mg/m2 associé au venetoclaxIl s'agit du quatrième patient à répondre à la combinaison sur un total de 4 patients traitésLe taux de réponse partielle est de 100 % (4/4), dont un patient en rémission complète, un en réponse quasi complète et deux en réponse partielleLes résultats ont été obtenus après le premier cycle de traitement (14 jours) chez des patients recevant un traitement de troisième ou quatrième ligne, dont deux avaient précédemment progressé sous venetoclax en association avec d'autres chimiothérapiesCes quatre patients présentent tous des profils cytogénétiques très difficiles à traiter, notamment un caryotype complexe, une mutation TP53, une mutation NRAS, une monosomie 5 et un réarrangement MECOM, qui sont généralement associés à un mauvais pronostic en raison de l'évolution agressive de la maladie et de la résistance au traitementCette diversité des patients répondeurs semble corroborer le mécanisme d'action d’AB8939, qui est capable de déstabiliser les microtubules en contournant la multirésistance aux médicaments et également en ciblant les cellules souches cancéreuses sans éliminer les cellules souches non tumorales Ces résultats confortent le positionnement d’AB8939 chez les patients présentant une génétique défavorable, des caryotypes complexes, des mutations TP53, NRAS et KRAS, une monosomie 5 et 7, et un réarrangement MECOM, qui représentent les besoins médicaux non staisfaits les plus importants iii)    Désignation de médicament orphelin auprès de l’EMA pour la molécule AB8939, dans le traitement dans le traitement de la leucémie myéloïde aigue (LMA)

AB Science a annoncé en avril 2025 que la molécule AB8939 a obtenu la désignation de médicament orphelin auprès du Comité des Médicaments Orphelins (COMP) de l’Agence Européenne des Médicaments (EMA), dans le traitement dans le traitement de la leucémie myéloïde aigue (LMA).

La molécule AB8939 avait déjà obtenu la désignation de médicament orphelin auprès de la Food and Drug Administration (FDA) américaine dans la LMA.

Cette obtention de désignation de médicament orphelin dans l’Union Européenne est une étape importante car cela signifie que le COMP a considéré que la molécule AB8939 présentait un bénéfice significatif pour les personnes atteintes de cette affection en plus des traitements existants.

iv)    Délivrance d’un brevet canadien protégeant la composition de matière d’AB8939, y compris son utilisation dans le traitement de la leucémie myéloïde aiguë, avec une protection jusqu’en 2036

AB Science a annoncé en juin 2025 que l'office des brevets du Canada a délivré un brevet (CA 2975644) protégeant la composition de matière d’AB8939, ainsi que des composés étroitement liés, jusqu'en 2036. Ce brevet couvre également l'utilisation d’AB8939 dans le traitement des troubles hématologiques et/ou des troubles prolifératifs et assure une protection globale solide pour le programme de développement clinique de d’AB8939, notamment le traitement de la leucémie myéloïde aiguë (LMA).

La délivrance de ce brevet complète également la couverture de la propriété intellectuelle pour AB8939 et la LMA dans toutes les zones géographiques où AB8939 pourrait être commercialisé.

En plus de la protection par brevet, AB8939 est également éligible à la protection réglementaire des données au Canada, empêchant la concurrence des génériques pendant une période de 8 ans à compter de l’enregistrement du produit.

Une seconde demande de brevet pour un usage médical a été déposée pour protéger l'utilisation d’AB8939 dans le traitement de la LMA avec certaines anomalies chromosomiques. Si cette demande est acceptée, la protection de l'AB8939 sera prolongée jusqu'en 2044 pour ces sous-populations de patients atteints de LMA.

AB Science a fait le point sur son programme de développement clinique AB Science a annoncé en avril 2026 une suspension volontaire et temporaire des essais cliniques en Europe et une Concentration des ressources sur la phase III du masitinib dans la SLA et la phase I de l'AB8939 dans la leucémie myéloïde aiguë (LMA).

Le recrutement de nouveaux patients dans les études européennes a été volontairement suspendu pendant la phase de négociation avec l'assureur de financement d'essai clinique (CTFI) et dans le cadre des échanges en cours avec les autorités sanitaires européennes, lesquelles ont soulevé des questions relatives aux ressources et au niveau de structuration de la Société pour la conduite d'essais cliniques en Europe. Des réponses détaillées ont été soumises aux agences. À cette occasion, AB Science a réexaminé ses priorités stratégiques

Dépriorisation des programmes en mastocytose et syndrome d'activation mastocytaire, dont le potentiel de marché est jugé inférieur aux coûts de développement ;Poursuite via partenariats du développement de phase III en sclérose en plaques et maladie d'Alzheimer, indications nécessitant des capacités commerciales dont AB Science ne dispose pas en propre ;Concentration des ressources sur la phase III du masitinib dans la SLA et la phase I de l'AB8939 dans la leucémie myéloïde aiguë (LMA). Compte tenu du stade d'avancement du pipeline, cet arrêt temporaire n'a pas d'impact opérationnel significatif : la phase III SLA n'a pas encore débuté, et la phase I AB8939 a récemment achevé son étape 3 (détermination de la MTD de l'AB8939 en association avec le vénétoclax sur 14 jours), le lancement de l'étape 4 (ajout de l'azacitidine) étant en attente d'autorisation réglementaire. AB Science renforcera par ailleurs son organisation afin de répondre aux exigences et préoccupations des autorités sanitaires préalablement au lancement de la phase III SLA et à la poursuite du programme AB8939.

ELEMENTS FINANCIERS CONSOLIDES POUR L’ANNEE 2025

Les produits d’exploitation sont exclusivement constitués du chiffre d’affaires lié à l’exploitation d’un médicament en médecine vétérinaire. Le chiffre d’affaires est en hausse de 10% par rapport au 31 décembre 2024 et s’élève à 1.174 milliers d’euros au 31 décembre 2025 contre 1.072 milliers d’euros au 31 décembre 2024 et 970 milliers d’euros un an plus tôt.

Les charges opérationnelles ont diminué de 93%, soit 6.620 milliers d’euros, entre les exercices clos les 31 décembre 2025 et 2024, après avoir diminué de 50% entre les exercices clos les 31 décembre 2024 et 2023.

Cette évolution au cours de l’exercice 2025 résulte principalement des éléments suivants :

Un événement non courant lié à l’annulation d’une avance remboursable de 4.432 milliers d’euros, comptabilisée en déduction des charges de recherche et développementUne baisse des charges administratives de 31%, soit 948 milliers d’euros, qui traduit la poursuite des efforts de maitrise des dépenses Une baisse des charges de recherche et développement, hors événement non-courant précité, de 40%, soit 1.594 milliers d’euros, qui traduit la poursuite des efforts de maitrise des dépenses et la focalisation des efforts de développent clinique en 2025 sur la molécule AB8939. En conséquence de ces évolutions, le déficit opérationnel a diminué de 6.270 milliers d’euros, soit une réduction de 111% entre les exercices clos le 31 décembre 2025 et le 31 décembre 2024 (passant de 6.083 milliers d’euros à profit de 639 milliers d’euros), après avoir diminué de 7.346 milliers d’euros (-55%) entre les exercices clos le 31 décembre 2024 et le 31 décembre 2023.

Hors événement non-courant, le déficit opérationnel a diminué de 2.290 milliers d’euros, soit une réduction de 38% entre les exercices clos le 31 décembre 2025 et le 31 décembre 2024 (passant de 6.083 milliers d’euros à 3.793 milliers d’euros).

Le résultat financier correspond à une perte de 2.196 milliers d’euros pour l’exercice clos le 31 décembre 2025, contre une perte de 1.749 milliers d’euros pour l’exercice clos le 31 décembre 2024 et un produit de 1.444 milliers d’euros pour l’exercice clos le 31 décembre 2023. Le gain de change de 984 milliers d’euros provient de calcul des gains définitifs non constatés des années antérieures du compte courant de la société AB Science USA, llc. Ce gain est sans impact sur la trésorerie.

Les autres produits financiers en 2024 s’élevaient à 469 milliers d’euros et étaient principalement liés :

à la variation de la juste valeur des BSA liés à l’emprunt BEI : gain de 143 milliers d’eurosà la variation de la juste valeur des ADPE : gain de 57 milliers d’eurosaux produits de 269 milliers d’euros liés à l’extinction d’une dette de locations (IFRS 16) dans le cadre d’une rupture anticipée de contrat Ces effets sont sans impact sur la trésorerie.

La perte nette pour les exercices clos le 31 décembre 2025 et 2024 s’est élevée respectivement à 1.557 milliers d’euros et 7.831 milliers d’euros, soit une baisse de 80% pour les raisons évoquées ci-dessus. Cette baisse fait suite à une diminution de 35% de la perte entres les exercices clos le 31 décembre 2024 et 2023.

Le tableau suivant résume les comptes consolidés annuels pour l’année 2025 établis conformément aux normes IFRS, et l’information comparative avec l’année 2024 :

 En milliers d’euros, sauf données par action31/12/202531/12/2024Chiffre d'affaires net1 1741 072Coût des ventes(196)176Charges de commercialisation(298)(316)Charges administratives(2 131)(3 079)Charges de recherche et développement(2 090)(3 936)Résultat opérationnel 639(6 083)Produits financiers 1 227678Charges financières (3 423)(2 427)Résultat financier (2 196)(1 749)Résultat net (1 557)(7 831)Résultat global de la période(1 422)(7 809)Résultat net par action - en euros(0,03)(0,15) Résultat net dilué par action - en euros(0,03)(0,15) En milliers d’euros31/12/202531/12/2024Trésorerie et équivalents de trésorerie10 1797 987Total de l’actif23 99923 175Capitaux propres (17 198)(23 754)Passifs non courants26 98026 496Dettes fournisseurs9 30010 028Passifs courants14 81520 433 AUTRES INFORMATIONS CORPORATE POUR L’ANNEE 2025 ET DEPUIS LE 31 DECEMBRE 2025

Augmentation de capital par placement privé pour un montant total de 9,5 millions d’euros

AB Science a annoncé en mai 2025 le succès d'une augmentation de capital d'un montant brut total de 1,8 million d’euros souscrite par un nombre limité d'investisseurs. Le Placement Privé, d'un montant total de EUR 1,8 million (prime d'émission incluse), a été réalisé par l'émission, sans droit préférentiel de souscription et sans délai de priorité, de 1.538.463 actions ordinaires nouvelles de la Société, chacune assortie d'un bon de souscription d'actions, dans le cadre d'une émission avec suppression du droit préférentiel de souscription des actionnaires au profit d'investisseurs relevant de la catégorie de personnes définie par la dix-huitième résolution de l'assemblée générale mixte des actionnaires de la Société du 26 juin 2024.

AB Science a annoncé en juillet 2025 le succès d'une augmentation de capital d'un montant brut total de 1,925 million d’euros souscrite par un nombre limité d'investisseurs. Le Placement Privé, d'un montant total de EUR 1,925 million (prime d'émission incluse), a été réalisé par l'émission, sans droit préférentiel de souscription et sans délai de priorité, de 1.644.355 actions ordinaires nouvelles de la Société, chacune assortie d'un bon de souscription, dans le cadre d'une émission avec suppression du droit préférentiel de souscription des actionnaires au profit d'investisseurs relevant de la catégorie de personnes définie par la seizième résolution de l'assemblée générale mixte des actionnaires de la Société du 30 juin 2025.

AB Science a annoncé en août 2025 le succès d'une augmentation de capital d'un montant brut total de 2,55 millions d’euros souscrite par un nombre limité d'investisseurs. Le Placement Privé, d'un montant total de EUR 2,55 millions (prime d'émission incluse), a été réalisé par l'émission, sans droit préférentiel de souscription et sans délai de priorité, de 2.276.787 actions ordinaires nouvelles de la Société, chacune assortie d'un bon de souscription d'actions, dans le cadre d'une émission avec suppression du droit préférentiel de souscription des actionnaires au profit d'investisseurs relevant de la catégorie de personnes définie par la seizième résolution de l'assemblée générale mixte des actionnaires de la Société du 30 juin 2025.

AB Science a annoncé en avril 2026 le succès d'une augmentation de capital d'un montant brut total de 3,2 millions d’euros souscrite par un nombre limité d'investisseurs. Le Placement Privé, d'un montant total de EUR 3,2 millions (prime d'émission incluse), a été réalisé par l'émission, sans droit préférentiel de souscription et sans délai de priorité, de 3.412.768 actions ordinaires nouvelles de la Société, chacune assortie d'un bon de souscription d'actions. Deux BSA permettent à leur porteur de souscrire à une action ordinaire de la Société au prix de EUR 1,30 par action ordinaire. L’émission a été réalisée dans le cadre de la seizième résolution de l'assemblée générale mixte des actionnaires de la Société du 30 juin 2025.

Le produit de ces Placements Privés fournira à AB Science les ressources supplémentaires nécessaires pour financer ses activités en cours, prioritairement la poursuite du développement clinique du programme AB8939.

Accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble de ses créanciers financiers

AB Science a annoncé en avril 2026 être parvenue à un accord définitif avec ses créanciers financiers. Cet accord prévoit un décalage de deux ans du remboursement des Prêts Garantis par l’Etat et un décalage de 12 mois de la date de remboursement du crédit BEI Covid. L’économie sur la période sera investie en R&D.

Un accord unanime des créanciers financiers a été obtenu sur les modalités de restructuration suivantes :

PGE pour un solde de 2,3 millions d’euros : i) une franchise en capital de 24 mois à compter de la date d’ouverture de la première procédure de conciliation au bénéfice d’AB Science, soit le 17 janvier 2025, avec reprise de l’amortissement à compter respectivement du 31 janvier 2027 pour Société Générale et du 2 février 2027 pour Banque Populaire ; ii) un allongement de la maturité de 24 mois reportant la date de maturité finale du 2 avril 2027 au 2 avril 2029 pour Banque Populaire et du 31 mars 2027 au 31 mars 2029 pour Société Générale ; iii) augmentation du taux d’intérêt uniquement pour refléter la modification du coût de refinancement. Prêt soutien innovation Bpifrance pour un solde de 1,25 million d’euros : i) une franchise en capital de 24 mois à compter du 1er novembre 2024 (échéance exigible au 31 janvier 2025) jusqu’au 31 octobre 2026 inclus (échéance en capital exigible au 31 janvier 2027) ; ii) un allongement de la maturité de 24 mois reportant la date de maturité finale du 30 avril 2027 au 30 avril 2029 ; iii) augmentation du taux d’intérêt uniquement pour refléter la modification du coût de refinancement. Contrat cadre d’aide au projet d’innovation stratégique industrielle Bpifrance pour un solde de 5,8 millions d’euros : Pour ce contrat qui prévoit, en cas de succès commercial du masitinib en neurologie, le remboursement de l’aide apportée par Bpifrance dans le cadre du projet de recherche intitulé ROMANE, les modalités de restructuration sont les suivantes : i ) une franchise en capital de 18 mois à compter du 30 juin 2026 jusqu’au 31 décembre 2027 ; ii) un allongement de la période des remboursements forfaitaires passant de 10 ans à 15 ans à compter du dernier versement de cette avance ; iii) un allongement de la période des remboursements complémentaires passant de 15 ans à 20 ans ; iv) une modification des montants des échéances annuelles. Crédit BEI Covid : Report de 12 mois de la date de maturité finale du Crédit BEI (avec une augmentation du taux d’intérêt de 100bps), de sorte que la date de maturité finale de la première tranche est reportée du 21 décembre 2028 au 21 décembre 2029 et que la date de maturité finale de la deuxième tranche est reportée du 28 janvier 2028 au 30 janvier 2029. Initiation de la couverture du titre AB Science par Maxim Group

AB Science a annoncé en décembre l’initiation de la couverture de son titre par Maxim Group, une société indépendante américaine spécialisée dans les services bancaires d'investissement, les titres et la gestion de patrimoine.

Dans cette étude, Maxim Group recommande l'achat du titre, avec un objectif de cours de 4,00 €.

L'étude souligne que « le masitinib a généré des bénéfices prometteurs dans trois maladies neurodégénératives, ce qui, selon nous, valide l'approche d'inhibition des mastocytes. Compte tenu des données d'efficacité sous-jacentes et du profil de tolérance, nous considérons que le profil bénéfice-risque du masitinib est positif. Au vu des données et des opportunités, nous commençons la couverture avec une recommandation d'achat et un objectif de cours de 4,00 €. Les données positives dans la SEP progressive et dans la maladie d’Alzheimer légère confirment encore son potentiel neuroprotecteur. Nous ne modélisons pas la maladie d’Alzheimer ni la SEP, et les considérons comme des opportunités à la hausse ».

Opérations sur les valeurs mobilières

Le Conseil d’administration a constaté lors de sa réunion du 3 janvier 2025 que les options de souscription d’actions ainsi que les bons de souscription d’actions listés ci-dessous sont désormais caducs, l’exerçabilité de ces titres étant conditionnée à l’obtention par la Société d’une autorisation de mise sur le marché du masitinib avant le 31 décembre 2024.

NatureIntituléDate d’attribution par le Conseil d’administrationBénéficiaireNombre de titresBSABSA 2021-A28/09/2021AMY SAS1.000.000BSABSA QN228/09/2021Quercegen800.000BSABSA QN328/09/2021Quercegen20.000SOSO2019-A20/05/2019Guy, Laurent274.000SOSO2019-B10/07/2019Guy, Laurent59.000 Le Conseil d’administration a constaté lors de sa réunion du 3 janvier 2025, après avoir passé en revue les termes et conditions des actions de préférence B (et en particulier les critères opérationnels et les critères de performance financière devant être atteints pour que les actions B puissent être converties en actions ordinaires), que sur un total de 45.134 actions B :

33.751 actions B1 ne peuvent pas être converties en actions ordinaires et doivent donc rachetées par la Société à leur valeur nominale en vue de leur annulation ; et180 actions B2 peuvent être converties en actions ordinaires selon un ratio de 1 : 2,43 (pour un ratio de conversion maximum de 1 : 100) ; et7.527 actions B3 peuvent être converties en actions ordinaires selon un ratio de 1 : 55,76 (pour un ratio de conversion maximum de 1 : 100) ; et3.676 actions B4 ne peuvent pas être converties en actions ordinaires et doivent donc rachetées par la Société à leur valeur nominale en vue de leur annulation Au 31 décembre 2025, sur la base des demandes de conversion reçues, 7.567 actions B2 et B3 ont été converties en 417.017 actions ordinaires, et le solde des actions B2 et B3 pouvant être converties en actions ordinaires est de 140.

Le 28 avril 2025, le Programme PACTTM a été prolongé à l’identique pour une durée de 12 mois. Il n’a fait l’objet d’aucune utilisation au cours de la période.

Le 30 avril 2025 ont été émises 15.000 actions gratuites (AGAP B’2). Ces actions gratuites seront attribuées définitivement en avril 2026.

Le 10 octobre 2025 ont été émises 1.025.000 actions gratuites sans conditions (AGSC) d’une valeur nominale de 0,01 euro et 4.754.708 actions gratuites avec conditions (AGAC) d’une valeur nominale de 0,01 euro, dont les conditions sont les suivantes :

Réalisation avec succès d’une étude de phase 3 d’enregistrement sur la sclérose latérale amyotrophique ou la sclérose en plaques, ou la maladie d’Alzheimer ou signature par AB Science d’un accord de licensing-out dans l’une de ces trois indications ; ou Réalisation avec succès d’une étude de phase 2 sur la Leucémie myéloide aigues ou signature par AB Science d’un accord de licensing-out dans cette indication ; ouRéalisation avec succès d’une étude de phase 2 sur la drépanocytose ou signature par AB Science d’un accord de licensing-out. L’attribution définitive de ces 1.025.000 AGSC et de ces 4.754.708 AGAC n’interviendra que le 8 octobre 2026.

Autres informations

AB Science confirme son éligibilité au PEA-PME conformément au décret n°2014-283 du 4 mars 2014 pris pour l’application de l’article 70 de la loi n°2013-1278 du 29 décembre 2013 de finances pour 2014 fixant l’éligibilité des entreprises au PEA-PME soit : moins de 5 000 salariés d’une part, un chiffre d’affaires annuel inférieur à 1,5 millions d’euros ou un total de bilan inférieur à 2 millions d’euros, d’autre part.

À propos d'AB Science
Fondée en 2001, AB Science est une société pharmaceutique spécialisée dans la recherche, le développement, et la commercialisation d'inhibiteurs de protéines kinases (IPK), une classe de protéines ciblées dont l'action est déterminante dans la signalisation cellulaire. Nos programmes ne ciblent que des pathologies à fort besoin médical, souvent mortelles avec un faible taux de survie, rares, ou résistantes à une première ligne de traitement.
AB Science a développé en propre un portefeuille de molécules et la molécule phare d'AB Science, le masitinib, a déjà fait l'objet d'un enregistrement en médecine vétérinaire et est développée chez l’homme en oncologie, dans les maladies neurodégénératives, dans les maladies inflammatoires et dans les maladies virales. La Société a son siège à Paris et est cotée sur Euronext Paris (Ticker : AB).

Plus d'informations sur la Société sur le site Internet : www.ab-science.com

Déclarations prospectives – AB Science
Ce communiqué contient des déclarations prospectives. Ces déclarations ne constituent pas des faits historiques. Ces déclarations comprennent des projections et des estimations ainsi que les hypothèses sur lesquelles celles-ci reposent, des déclarations portant sur des projets, des objectifs, des intentions et des attentes concernant des résultats financiers, des événements, des opérations, des services futurs, le développement de produits et leur potentiel ou les performances futures.
Ces déclarations prospectives peuvent souvent être identifiées par les mots « s'attendre à », « anticiper », « croire », « avoir l'intention de », « estimer » ou « planifier », ainsi que par d'autres termes similaires. Bien qu’AB Science estime que ces déclarations prospectives sont raisonnables, les investisseurs sont alertés sur le fait que ces déclarations prospectives sont soumises à de nombreux risques et incertitudes, difficilement prévisibles et généralement en dehors du contrôle d’AB Science qui peuvent impliquer que les résultats et événements effectifs réalisés diffèrent significativement de ceux qui sont exprimés, induits ou prévus dans les informations et déclarations prospectives. Ces risques et incertitudes comprennent notamment les incertitudes inhérentes aux développements des produits de la Société, qui pourraient ne pas aboutir, ou à la délivrance par les autorités compétentes des autorisations de mise sur le marché ou plus généralement tous facteurs qui peuvent affecter la capacité de commercialisation des produits développés par AB Science ainsi que ceux qui sont développés ou identifiés dans les documents publics publiés par AB Science. AB Science ne prend aucun engagement de mettre à jour les informations et déclarations prospectives sous réserve de la réglementation applicable notamment les articles 223-1 et suivants du règlement général de l’AMF.

Pour tout renseignement complémentaire, merci de contacter :

AB Science  Communication financière
[email protected]

AB SCIENCE Resultats 2025 VFR VF

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.

Copyright 2026 Zacks Investment Research 101 N Wacker Drive, Floor 15, Chicago, IL 60606

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.

Visit Performance Disclosure for information about the performance numbers displayed above.

Visit www.zacksdata.com to get our data and content for your mobile app or website.

Real time prices by BATS. Delayed quotes by Sungard.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.

This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.

NEW YORK, May 22, 2026 /PRNewswire/ -- AllianceBernstein National Municipal Income Fund, Inc. [NYSE: AFB] (the "Fund") today released its monthly portfolio update as of April 30, 2026. AllianceBernstein National Municipal Income Fund, Inc. Top 10 Fixed-Income Holdings Portfolio % 1) San Francisco Intl Airport Series 2026-2 5.50%, 05/01/55 3.72 % 2) Melissa Independent School District Series 2024-2 4.25%, 02/01/53 2.16 % 3) Commonwealth of Massachusetts Series 2025-2 5.00%, 01/01/54 2.00 % 4) Oklahoma Turnpike Authority Series 2023 4.50%, 01/01/53 1.97 % 5) New York Transportation Development Corp. Series 2024 Zero Coupon, 12/31/54 1.96 % 6) Dallas Independent School District Series 2024-2 4.00%, 02/15/54 1.91 % 7) State of Hawaii Airports System Revenue Series 2025-2 5.50%, 07/01/54 1.87 % 8) City of Atlanta GA Department of Aviation Series 2025-2 5.50%, 07/01/55 1.86 % 9) Worthington City School District Series 2025-2 5.50%, 12/01/54 1.85 % 10) Metropolitan Washington Airports Authority Aviation Revenue Series 2025-2 5.50%, 10/01/55 1.85 % Sector/Industry Breakdown Portfolio % Revenue Airport 13.65 % Health Care - Not-for-Profit 11.04 % Revenue - Miscellaneous 7.51 % Toll Roads/Transit 5.89 % Industrial Development - Airline 5.17 % Prepay Energy 4.63 % Primary/Secondary Ed.

COMMUNIQUÉ DE PRESSE

À LA SUITE DE LA PUBLICATION DES RÉSULTATS DE L'EXERCICE 2025 ET DE LA SOUSCRIPTION D'UNE ASSURANCE POUR LES ESSAIS CLINIQUES, MAXIM GROUP RÉITÈRE SA RECOMMANDATION D'ACHAT SUR LE TITRE AB SCIENCE AVEC UN OBJECTIF DE COURS DE 4,0 EUR PAR ACTION

Paris, 25 mai 2026, 18h

AB Science SA (Euronext - FR0010557264 - AB) annonce que le titre AB Science continue d’être couvert par Maxim Group, une société indépendante américaine spécialisée dans les services bancaires d'investissement, les titres et la gestion de patrimoine, qui a réitéré sa recommandation d’achat sur le titre avec un objectif de cours de 4,00 € par action.

Maxim Group a publié cette recommandation dans une note intitulée “2H25 Review/Outlook: With Masitinib Clinical Trial Insurance Policy Offer, Positioned to Initiate Phase 3 Study for ALS in 2H26”, publiée le 21 mai 2026.

Dans cette mise à jour, Maxim Group a réitéré sa recommandation d’achat du titre, avec un objectif de cours de 4,00 €.

La nouvelle note souligne que :

En avril 2026, une offre de souscription d’une police d’assurance de financement d’essais cliniques d’un montant de 25 millions d’euros (jusqu’à 39 millions d’euros) a été obtenue afin de se prémunir contre un échec de la phase 3 et les coûts associés, et divers accords de crédit ont été renégociés.AB Science donne désormais la priorité stratégique totale au développement du masitinib pour la SLA et d’AB8939 pour la leucémie myéloïde aiguë (LMA). Tous ses essais cliniques et développements dans les autres indications en dehors de la SLA et de la LMA ont été volontairement suspendus dans le cadre de ce recentrage stratégique. Cela devrait permettre de réduire les coûts d’exploitation tout en accélérant le développement des programmes présentant la plus grande valeur. Le masitinib pour le traitement de la SLA reste la voie la plus rapide vers la commercialisation.Bien qu'un financement soit nécessaire pour lancer l'étude de phase 3 sur le masitinib dans le traitement de la SLA, la police d'assurance des essais cliniques réduit considérablement le risque pour AB Science auprès des investisseurs existants et potentiels qui financent le programme de phase 3. Elle fonctionne en effet comme une option de vente : bien qu'une prime de 8 millions d'euros doive être versée, les investisseurs bénéficient d'une protection de 25 millions d'euros si l'essai échoue et peuvent potentiellement récupérer leur capital initial, à hauteur des coûts de l'essai. Cela rend l'opportunité de financement et d'investissement pour AB Science plus attractive grâce à cette protection contre les pertes.Dans l'ensemble, le masitinib a montré un potentiel prometteur pour le traitement des patients atteints de SLA et ayant une progression normale de la maladie, avec un profil risque-bénéfice positif. Dans la SLA, le masitinib a démontré des bénéfices tant fonctionnels qu'en termes de survie, tout en étant bien toléré. De plus, le masitinib a généré des résultats prometteurs dans trois maladies neurodégénératives (SLA, SEP, maladie d’Alzheimer), ce qui valide globalement l'approche d'inhibition des mastocytes. Cette recommandation confirme la couverture de l'action AB Science par Maxim Group, qui s'ajoute au consensus des analystes financiers aux côtés de Chardan, In Extenso Finance et DNA Finance.

À propos d'AB Science
Fondée en 2001, AB Science est une société pharmaceutique spécialisée dans la recherche, le développement et la commercialisation d’inhibiteurs de protéines kinases (PKI), une classe de protéines ciblées dont l’action est essentielle dans les voies de signalisation au sein des cellules. Nos programmes ciblent uniquement des maladies présentant des besoins médicaux non satisfaits importants, qui sont souvent mortelles avec une survie à court terme, ou rares, ou encore réfractaires aux traitements existants.

AB Science a développé un portefeuille exclusif de molécules, et le composé phare de la société, le masitinib, a déjà été homologué en médecine vétérinaire et est en cours de développement pour la médecine humaine. La société a son siège social à Paris, en France, et est cotée sur Euronext Paris (symbole boursier : AB).

De plus amples informations sont disponibles sur le site web d’AB Science : www.ab-science.com.

Déclarations prospectives - AB Science

Ce communiqué de presse contient des déclarations prospectives. Ces déclarations ne sont pas des faits historiques. Elles comprennent des projections et des estimations ainsi que les hypothèses sur lesquelles elles reposent, des déclarations fondées sur des projets, des objectifs, des intentions et des attentes concernant les résultats financiers, les événements, les opérations, les services futurs, le développement de produits et leurs performances potentielles ou futures.

Ces déclarations prospectives peuvent souvent être identifiées par les mots « s'attendre à », « anticiper », « croire », « avoir l'intention de », « estimer » ou « prévoir », ainsi que par d'autres termes similaires. Bien qu’AB Science estime que ces déclarations prospectives sont raisonnables, les investisseurs sont avertis que ces déclarations prospectives sont soumises à de nombreux risques et incertitudes difficiles à prévoir et généralement hors du contrôle d’AB Science, ce qui peut impliquer que les résultats et les événements réels diffèrent sensiblement de ceux exprimés, suggérés ou anticipés dans les informations et déclarations prospectives. Ces risques et incertitudes comprennent les incertitudes liées au développement des produits de la Société, qui pourrait ne pas aboutir, ou aux autorisations de mise sur le marché accordées par les autorités compétentes, ou, plus généralement, à tout facteur susceptible d’affecter la capacité de commercialisation des produits développés par AB Science, ainsi qu’à ceux développés ou identifiés dans les documents publics publiés par AB Science. AB Science décline toute obligation ou engagement de mettre à jour les informations et déclarations prospectives, sous réserve des réglementations applicables, en particulier les articles 223-1 et suivants du Règlement général de l’AMF.

Pour plus d'informations, veuillez contacter :

AB Science

Communication financière et relations avec les médias

[email protected]

CP_Reiteration_Maxim_VFR VF CP_Reiteration_Maxim_VFR VF

, /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management increased to $899 billion in May 2026, up from $882 billion at the end of April. The 2% increase in month-end AUM was driven by market appreciation, partially offset by net outflows. May outflows were concentrated in Retail, while Institutions saw modest inflows and Private Wealth flows were roughly flat.

AllianceBernstein L.P. (The Operating Partnership)

Assets Under Management ($ in Billions)

At May 31, 2026

Apr 30,

2026

Private

Institutions

Retail

Wealth

Total

Total

Equity

Actively Managed

$

51

$

169

$

64

$

284

$

278

Passive

31

44

11

86

82

Total Equity

82

213

75

370

360

Fixed Income

Taxable

120

67

22

209

209

Tax-Exempt

1

63

33

97

95

Passive

—

9

—

9

9

Total Fixed Income

121

139

55

315

313

Alternatives/Multi-Asset
Solutions(1)

167

10

37

214

209

Total

$

370

$

362

$

167

$

899

$

882

At April 30, 2026

Total

$

363

$

356

$

163

$

882

(1) Includes certain multi-asset solutions and services not included in equity or fixed income services.

Cautions Regarding Forward-Looking Statements

Certain statements provided by management in this news release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. The most significant of these factors include, but are not limited to, the following: the performance of financial markets, the investment performance of sponsored investment products and separately-managed accounts, general economic conditions, industry trends, future acquisitions, integration of acquired companies, competitive conditions, and government regulations, including changes in tax regulations and rates and the manner in which the earnings of publicly-traded partnerships are taxed. AB cautions readers to carefully consider such factors. Further, such forward-looking statements speak only as of the date on which such statements are made; AB undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. For further information regarding these forward-looking statements and the factors that could cause actual results to differ, see "Risk Factors" and "Cautions Regarding Forward-Looking Statements" in AB's Form 10-K for the year ended December 31, 2025 or form 10-Q for the quarter ended March 31, 2026. Any or all of the forward-looking statements made in this news release, Form 10-K, Form 10-Q, other documents AB files with or furnishes to the SEC and any other public statements issued by AB, may turn out to be wrong. It is important to remember that other factors besides those listed in "Risk Factors" and "Cautions Regarding Forward-Looking Statements", and those listed above, could also adversely affect AB's financial condition, results of operations and business prospects.

About AllianceBernstein

AllianceBernstein is a leading global investment management firm that offers diversified investment services to institutional investors, individuals and private wealth clients in major world markets.

As of March 31, 2026, including both the general partnership and limited partnership interests in AllianceBernstein, AllianceBernstein Holding owned approximately 31.4% of AllianceBernstein. Including both the general partnership and limited partnership interest in AllianceBernstein Holding and AllianceBernstein, Equitable Holdings, Inc. ("EQH"), owned an approximate 68.0% economic interest in AllianceBernstein.

Additional information about AB may be found on our website, www.alliancebernstein.com.

SOURCE AllianceBernstein

Copart, Inc. (CPRT - Free Report) closed the most recent trading day at $33.25, moving +1.5% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 1.02%. Elsewhere, the Dow gained 0.63%, while the tech-heavy Nasdaq added 1.23%.

Shares of the company have depreciated by 3.9% over the course of the past month, underperforming the Business Services sector's loss of 3.89%, and the S&P 500's gain of 0.63%.

Analysts and investors alike will be keeping a close eye on the performance of Copart, Inc. in its upcoming earnings disclosure. In that report, analysts expect Copart, Inc. to post earnings of $0.42 per share. This would mark no growth from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $1.23 billion, showing a 1.6% escalation compared to the year-ago quarter.

For the full year, the Zacks Consensus Estimates project earnings of $1.58 per share and a revenue of $4.65 billion, demonstrating changes of -0.63% and -0.03%, respectively, from the preceding year.

It's also important for investors to be aware of any recent modifications to analyst estimates for Copart, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Currently, Copart, Inc. is carrying a Zacks Rank of #4 (Sell).

From a valuation perspective, Copart, Inc. is currently exchanging hands at a Forward P/E ratio of 20.68. This expresses a discount compared to the average Forward P/E of 22.84 of its industry.

The Auction and Valuation Services industry is part of the Business Services sector. This group has a Zacks Industry Rank of 200, putting it in the bottom 19% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

Posted by Defense World Staff on Apr 19th, 2026

Shares of Copart, Inc. (NASDAQ:CPRT – Get Free Report) have earned an average recommendation of “Hold” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation, one has issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $44.40.

CPRT has been the topic of a number of analyst reports. Weiss Ratings restated a “hold (c-)” rating on shares of Copart in a research report on Monday, March 23rd. Zacks Research lowered shares of Copart from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 24th. JPMorgan Chase & Co. decreased their target price on shares of Copart from $45.00 to $34.00 and set a “neutral” rating on the stock in a research report on Monday, February 23rd. Robert W. Baird set a $48.00 target price on shares of Copart and gave the stock an “outperform” rating in a research report on Friday, February 20th. Finally, Barclays restated an “underweight” rating and set a $32.00 target price (down from $33.00) on shares of Copart in a research report on Monday, February 23rd.

Read Our Latest Stock Analysis on Copart

Insider Transactions at Copart In related news, CEO Jeffrey Liaw sold 26,213 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $33.18, for a total transaction of $869,747.34. Following the sale, the chief executive officer owned 79,532 shares in the company, valued at approximately $2,638,871.76. This trade represents a 24.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 9.60% of the company’s stock.

Hedge Funds Weigh In On Copart Hedge funds have recently made changes to their positions in the stock. Cloud Capital Management LLC acquired a new position in shares of Copart in the 3rd quarter valued at $25,000. Tripletail Wealth Management LLC acquired a new position in shares of Copart in the 3rd quarter valued at $27,000. Lodestone Wealth Management LLC acquired a new position in shares of Copart in the 4th quarter valued at $25,000. LRI Investments LLC boosted its holdings in shares of Copart by 125.2% in the 3rd quarter. LRI Investments LLC now owns 653 shares of the business services provider’s stock valued at $29,000 after purchasing an additional 363 shares during the last quarter. Finally, Cornerstone Planning Group LLC boosted its holdings in shares of Copart by 54.0% in the 3rd quarter. Cornerstone Planning Group LLC now owns 730 shares of the business services provider’s stock valued at $31,000 after purchasing an additional 256 shares during the last quarter. Institutional investors and hedge funds own 85.78% of the company’s stock.

Copart Trading Up 0.5% Shares of Copart stock opened at $33.45 on Friday. Copart has a 12-month low of $32.20 and a 12-month high of $63.85. The stock has a market cap of $32.22 billion, a PE ratio of 20.91 and a beta of 1.14. The company has a 50-day moving average of $35.18 and a two-hundred day moving average of $38.97.

Copart (NASDAQ:CPRT – Get Free Report) last issued its earnings results on Thursday, February 19th. The business services provider reported $0.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.15 billion. Copart had a net margin of 33.76% and a return on equity of 16.68%. The company’s quarterly revenue was down 3.6% on a year-over-year basis. During the same period last year, the business posted $0.40 earnings per share. On average, sell-side analysts forecast that Copart will post 1.57 EPS for the current fiscal year.

Copart Company Profile (Get Free Report)

Copart (NASDAQ: CPRT) is a global provider of online vehicle auction and remarketing services, focused primarily on the sale of salvage and clean-title vehicles. The company operates a technology-driven auction platform that connects sellers — including insurance companies, vehicle finance firms, rental car companies, dealerships and fleet owners — with a broad buyer base consisting of vehicle dismantlers, recyclers, rebuilders and retail buyers. Copart’s business model centers on efficient vehicle disposition using digital bidding and logistics services to maximize recovery value for its clients.

Core services include hosting live and timed online auctions, vehicle listing and inspection support, title processing, and transportation and storage solutions.

Featured Stories Five stocks we like better than Copart

Receive News & Ratings for Copart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Copart and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINETTM Technologies, Inc. (NASDAQ:TTMI) Receives Consensus Rating of “Moderate Buy” from Brokerages

NEXT HEADLINE »Royal Bank Of Canada Raises MeiraGTx (NASDAQ:MGTX) Price Target to $24.00

Posted by Defense World Staff on Apr 22nd, 2026

Davidson Kahn Capital Management LLC grew its holdings in Copart, Inc. (NASDAQ:CPRT – Free Report) by 56.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 100,151 shares of the business services provider’s stock after buying an additional 36,091 shares during the period. Copart makes up 2.0% of Davidson Kahn Capital Management LLC’s portfolio, making the stock its 13th largest holding. Davidson Kahn Capital Management LLC’s holdings in Copart were worth $3,921,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cloud Capital Management LLC purchased a new position in shares of Copart in the 3rd quarter worth $25,000. Tripletail Wealth Management LLC purchased a new position in shares of Copart during the 3rd quarter worth about $27,000. Lodestone Wealth Management LLC purchased a new position in shares of Copart during the 4th quarter worth about $25,000. LRI Investments LLC boosted its stake in shares of Copart by 125.2% during the 3rd quarter. LRI Investments LLC now owns 653 shares of the business services provider’s stock worth $29,000 after purchasing an additional 363 shares during the period. Finally, Cornerstone Planning Group LLC boosted its stake in shares of Copart by 54.0% during the 3rd quarter. Cornerstone Planning Group LLC now owns 730 shares of the business services provider’s stock worth $31,000 after purchasing an additional 256 shares during the period. 85.78% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets In related news, CEO Jeffrey Liaw sold 26,213 shares of Copart stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $33.18, for a total transaction of $869,747.34. Following the completion of the sale, the chief executive officer owned 79,532 shares in the company, valued at $2,638,871.76. This trade represents a 24.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 9.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In A number of equities analysts recently commented on CPRT shares. Robert W. Baird set a $48.00 price target on shares of Copart and gave the stock an “outperform” rating in a research note on Friday, February 20th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Copart in a research note on Monday, March 23rd. JPMorgan Chase & Co. dropped their price target on shares of Copart from $45.00 to $34.00 and set a “neutral” rating for the company in a research note on Monday, February 23rd. Zacks Research cut shares of Copart from a “hold” rating to a “strong sell” rating in a research note on Tuesday, February 24th. Finally, Barclays reaffirmed an “underweight” rating and set a $32.00 price target (down from $33.00) on shares of Copart in a research note on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $44.40.

View Our Latest Report on Copart

Copart Price Performance Shares of CPRT opened at $33.74 on Wednesday. Copart, Inc. has a 1-year low of $32.20 and a 1-year high of $63.85. The company has a 50-day moving average of $34.92 and a 200 day moving average of $38.77. The firm has a market capitalization of $32.50 billion, a price-to-earnings ratio of 21.09 and a beta of 1.14.

Copart (NASDAQ:CPRT – Get Free Report) last announced its quarterly earnings data on Thursday, February 19th. The business services provider reported $0.36 earnings per share for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). Copart had a net margin of 33.76% and a return on equity of 16.68%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same quarter in the previous year, the business earned $0.40 EPS. The company’s quarterly revenue was down 3.6% compared to the same quarter last year. On average, equities analysts anticipate that Copart, Inc. will post 1.58 earnings per share for the current fiscal year.

About Copart (Free Report)

Copart (NASDAQ: CPRT) is a global provider of online vehicle auction and remarketing services, focused primarily on the sale of salvage and clean-title vehicles. The company operates a technology-driven auction platform that connects sellers — including insurance companies, vehicle finance firms, rental car companies, dealerships and fleet owners — with a broad buyer base consisting of vehicle dismantlers, recyclers, rebuilders and retail buyers. Copart’s business model centers on efficient vehicle disposition using digital bidding and logistics services to maximize recovery value for its clients.

Core services include hosting live and timed online auctions, vehicle listing and inspection support, title processing, and transportation and storage solutions.

Recommended Stories Five stocks we like better than Copart Want to see what other hedge funds are holding CPRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Copart, Inc. (NASDAQ:CPRT – Free Report).

Receive News & Ratings for Copart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Copart and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEIron Mountain (NYSE:IRM) Reaches New 52-Week High – Should You Buy?

NEXT HEADLINE »Calamos Dynamic Convertible and Income Fund (NASDAQ:CCD) Stock Price Crosses Above 50-Day Moving Average – Time to Sell?

Posted by Defense World Staff on Apr 26th, 2026

HB Wealth Management LLC lessened its holdings in Copart, Inc. (NASDAQ:CPRT – Free Report) by 48.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,868 shares of the business services provider’s stock after selling 42,539 shares during the quarter. HB Wealth Management LLC’s holdings in Copart were worth $1,757,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Davidson Kahn Capital Management LLC grew its holdings in Copart by 56.3% in the fourth quarter. Davidson Kahn Capital Management LLC now owns 100,151 shares of the business services provider’s stock worth $3,921,000 after purchasing an additional 36,091 shares during the period. Novem Group grew its holdings in Copart by 42.9% in the fourth quarter. Novem Group now owns 23,951 shares of the business services provider’s stock worth $938,000 after purchasing an additional 7,187 shares during the period. Legacy Advisors LLC grew its holdings in Copart by 6.5% in the fourth quarter. Legacy Advisors LLC now owns 8,041 shares of the business services provider’s stock worth $315,000 after purchasing an additional 494 shares during the period. TD Waterhouse Canada Inc. grew its holdings in Copart by 40.7% in the fourth quarter. TD Waterhouse Canada Inc. now owns 6,415 shares of the business services provider’s stock worth $251,000 after purchasing an additional 1,855 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Copart by 102.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 456,870 shares of the business services provider’s stock worth $17,886,000 after purchasing an additional 230,957 shares during the period. Hedge funds and other institutional investors own 85.78% of the company’s stock.

Insider Activity In other news, CEO Jeffrey Liaw sold 26,213 shares of Copart stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $33.18, for a total value of $869,747.34. Following the completion of the sale, the chief executive officer directly owned 79,532 shares in the company, valued at $2,638,871.76. The trade was a 24.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 9.60% of the stock is currently owned by insiders.

Copart Price Performance Shares of NASDAQ:CPRT opened at $33.07 on Friday. Copart, Inc. has a 1 year low of $32.20 and a 1 year high of $63.85. The company has a market cap of $31.86 billion, a P/E ratio of 20.67 and a beta of 1.14. The stock’s fifty day moving average price is $34.66 and its 200-day moving average price is $38.58.

Copart (NASDAQ:CPRT – Get Free Report) last released its quarterly earnings data on Thursday, February 19th. The business services provider reported $0.36 EPS for the quarter, missing the consensus estimate of $0.39 by ($0.03). Copart had a return on equity of 16.68% and a net margin of 33.76%.The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.15 billion. During the same quarter in the previous year, the business posted $0.40 earnings per share. Copart’s quarterly revenue was down 3.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Copart, Inc. will post 1.58 earnings per share for the current year.

Analyst Ratings Changes A number of equities research analysts have weighed in on the stock. Robert W. Baird set a $48.00 price objective on shares of Copart and gave the stock an “outperform” rating in a report on Friday, February 20th. JPMorgan Chase & Co. cut their price objective on shares of Copart from $45.00 to $34.00 and set a “neutral” rating on the stock in a report on Monday, February 23rd. Zacks Research cut shares of Copart from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 24th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Copart in a report on Monday, March 23rd. Finally, Barclays reiterated an “underweight” rating and set a $32.00 price target (down from $33.00) on shares of Copart in a report on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Copart has a consensus rating of “Hold” and an average price target of $44.40.

Get Our Latest Research Report on CPRT

Copart Profile (Free Report)

Copart (NASDAQ: CPRT) is a global provider of online vehicle auction and remarketing services, focused primarily on the sale of salvage and clean-title vehicles. The company operates a technology-driven auction platform that connects sellers — including insurance companies, vehicle finance firms, rental car companies, dealerships and fleet owners — with a broad buyer base consisting of vehicle dismantlers, recyclers, rebuilders and retail buyers. Copart’s business model centers on efficient vehicle disposition using digital bidding and logistics services to maximize recovery value for its clients.

Core services include hosting live and timed online auctions, vehicle listing and inspection support, title processing, and transportation and storage solutions.

See Also Five stocks we like better than Copart Want to see what other hedge funds are holding CPRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Copart, Inc. (NASDAQ:CPRT – Free Report).

Receive News & Ratings for Copart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Copart and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEConfluence Wealth Services Inc. Cuts Stake in ExxonMobil Corporation $XOM

NEXT HEADLINE »Brindle & Bay Financial Advisors LLC Buys Shares of 4,999 PepsiCo, Inc. $PEP

Copart, Inc. (CPRT - Free Report) closed at $33.87 in the latest trading session, marking a +1.44% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.38%. At the same time, the Dow lost 0.63%, and the tech-heavy Nasdaq lost 0.13%.

Shares of the company witnessed a gain of 0.66% over the previous month, trailing the performance of the Business Services sector with its gain of 4.25%, and the S&P 500's gain of 11.41%.

The upcoming earnings release of Copart, Inc. will be of great interest to investors. The company is expected to report EPS of $0.42, unchanged from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.23 billion, up 1.6% from the prior-year quarter.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.58 per share and a revenue of $4.65 billion, indicating changes of -0.63% and -0.03%, respectively, from the former year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Copart, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. At present, Copart, Inc. boasts a Zacks Rank of #3 (Hold).

Looking at valuation, Copart, Inc. is presently trading at a Forward P/E ratio of 21.08. For comparison, its industry has an average Forward P/E of 26.21, which means Copart, Inc. is trading at a discount to the group.

The Auction and Valuation Services industry is part of the Business Services sector. This industry currently has a Zacks Industry Rank of 43, which puts it in the top 18% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

In the latest trading session, Copart, Inc. (CPRT - Free Report) closed at $32.94, marking a -1.5% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.59%. At the same time, the Dow lost 0.14%, and the tech-heavy Nasdaq gained 1.2%.

Shares of the company have appreciated by 0.45% over the course of the past month, underperforming the Business Services sector's gain of 4.25%, and the S&P 500's gain of 8.64%.

Investors will be eagerly watching for the performance of Copart, Inc. in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.42, marking stability compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $1.23 billion, showing a 1.6% escalation compared to the year-ago quarter.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.58 per share and revenue of $4.65 billion, indicating changes of -0.63% and -0.03%, respectively, compared to the previous year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Copart, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Copart, Inc. currently has a Zacks Rank of #3 (Hold).

Looking at valuation, Copart, Inc. is presently trading at a Forward P/E ratio of 21.11. This denotes a discount relative to the industry average Forward P/E of 23.65.

The Auction and Valuation Services industry is part of the Business Services sector. This industry, currently bearing a Zacks Industry Rank of 47, finds itself in the top 20% echelons of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

On May 21, 2026, Copart Inc (CPRT) released its 8-K filing reporting fiscal third quarter 2026 results for the period ended April 30, 2026. Quarterly revenue wa

3 Stocks With Monopoly Power—and Minimal CompetitionCopart NASDAQ: CPRT reported higher revenue and profit for its fiscal third quarter of 2026, even as insurance unit volumes declined amid softer claims activity and shifting consumer insurance behavior.

Chief Executive Officer Jeff Liaw said global insurance unit sales fell 2.7% in the quarter, or 1.9% excluding the impact of catastrophe-related volumes from the prior year. In the U.S., insurance unit volume declined 4.2%, or just over 3% excluding those catastrophic units.

Get Copart alerts:

3 Oversold Stocks Flashing Bullish Reversal SignalsLiaw said the company continues to believe the long-term growth outlook for its insurance business remains intact, citing a multiyear pattern in which modest declines in accident frequency have been more than offset by increases in total loss frequency. He said total loss frequency is being driven by rising repair costs and by Copart’s ability to generate strong auction returns by finding “the highest and best use” for vehicles globally.

Revenue rises despite lower unit volumes Chief Financial Officer Leah Stearns said consolidated revenue rose 2.1% year over year to $1.24 billion. The increase was driven by strength in service revenue and purchased vehicle sales, while average selling prices rose 4.6%, more than offsetting a 2.4% decline in total unit volumes.

These 2 Auto Stocks Are Profiting as Used Cars and Parts ThriveGlobal gross profit increased 3.7% to $572.6 million, and gross margin expanded 71 basis points to 46.3%. Operating income rose 2.8% to $464.3 million. Net income was $402.4 million, while diluted earnings per share increased 2.4% to $0.43, which Stearns said benefited in part from share repurchases.

Copart ended the quarter with approximately $5.5 billion of liquidity, including $4.2 billion in cash, equivalents and held-to-maturity securities, and no debt. Stearns said year-to-date free cash flow increased 12%, supported by capital allocation into land, facilities and technology.

The company has repurchased more than 43.4 million shares so far in fiscal 2026 for more than $1.6 billion through a combination of 10b5-1 and open market transactions.

Insurance volumes pressured by consumer pullback Liaw attributed near-term volume softness partly to policy-in-force mix shifts among insurance carriers and to reduced claims activity as consumers respond to higher premiums. He cited ISS Fast Track data showing earned car years declined 4% year over year in the fourth calendar quarter of 2025, while vehicles in operation grew 1.4%.

“We believe this divergence, declining insurance coverage against a growing vehicle fleet, is clear evidence of the consumer pullback on insurance coverage,” Liaw said.

He also cited CCC data indicating that 25% of repairs are now self-pay, saying consumers are absorbing more of the financial burden of claims. Liaw said this behavior has historically been cyclical, with consumers reducing coverage when they feel pressure from insurance costs and later adjusting as conditions change.

Total loss frequency reached 23.6% in the first calendar quarter of 2026, an increase of nearly five percentage points over four years, Liaw said. He added that Copart sees itself as an active driver of that trend by improving auction returns and making total loss decisions more attractive to insurers.

U.S. segment flat as international business expands In the U.S., total units declined 4.2%, or 3.3% excluding Copart Direct units. Insurance volumes were down 4.2%. U.S. inventory declined 4.7% year over year, and assignments were down at a low single-digit pace.

Stearns said momentum remained positive across parts of Copart’s diversified seller base. Dealer Services and powersports units grew 1%, while the Blue Car commercial consignment channel expanded more than 4%. Combined fleet and finance seller volume grew at a double-digit pace, partly offset by higher repair activity among rental customers. Copart Direct unit volume declined 26.3% as the company continued to shift lower-value units to its direct buy channel.

U.S. revenue was essentially flat, down 0.4%, as higher revenue per unit offset volume pressure. U.S. gross profit rose 0.9% to $484.1 million, with a gross margin of 48.3%. U.S. operating income was $390.4 million, representing a 38.9% operating margin.

Internationally, total units sold increased 5.9%, including a 4.6% increase in insurance units and an 11.2% gain in non-insurance units. International inventory rose more than 10% year over year, and assignments increased at a low-teens pace. Stearns cited broad-based growth, with particularly strong contributions from the U.K., Germany and Canada.

International revenue increased 14.1% to $234.2 million, or 7.9% excluding foreign currency effects. Service revenue rose 17.9%, driven by a 10.5% increase in fee revenue per unit and stronger volumes. International gross profit increased 21.9%, and operating income reached $73.8 million, a 31.5% operating margin.

Auction returns and buyer network remain key focus Liaw said U.S. insurance average selling prices increased 4.1% year over year and reached a seasonally adjusted record high for Copart insurance ASPs in the third quarter. He said international buyers remain a critical driver of auction returns, accounting for more than one-third of the volume sold at U.S. Copart auctions and nearly half of auction proceeds.

Although participation from some Middle Eastern markets declined amid recent conflicts, Liaw said demand was supported by growth from other regions, including parts of Central Europe, West Africa, Central America and the Caribbean. Copart’s buyer network now spans more than 160 countries, he said.

Liaw also highlighted “crossover buyers,” or members who first come to Copart through non-insurance vehicles sold by rental car companies, financial institutions or dealers, and then begin bidding on insurance vehicles. He said that over the past three years, a majority of more than 30,000 buyers who first entered through non-insurance vehicles bid on an insurance vehicle within their first 90 days.

The company also said more U.S. insurance sellers are using “pure sale” auctions, which Liaw confirmed are non-reserve sales. He said the mix of pure sale units among U.S. insurance sellers is at an all-time high.

Management discusses growth initiatives During the question-and-answer session, Liaw identified several long-term growth drivers, including continued increases in total loss frequency, expansion among non-insurance sellers such as rental car companies, dealers, fleets and financial institutions, and international growth.

Stearns said Purple Wave, Copart’s industrial equipment auction platform, generated more than 25% gross transaction value growth over the last 12 months. She said the business has expanded its territory sales force beyond its original central U.S. focus and has grown its team to roughly 2.5 to 3 times its size at acquisition.

Stearns also discussed Copart’s long-haul delivery service, saying the company shifted the offering a little over 12 months ago and has seen rapid adoption. She said the service added about $15 million year over year to facility operations costs in the quarter while also generating margin at the revenue line.

Liaw said Copart recently held its 2026 Insurance Advisory Board meeting with major U.S. insurance clients, where topics included artificial intelligence deployment. He said insurers are exploring AI across their businesses, including claims, underwriting and pricing, while also being cautious because claims decisions must be auditable and accountable.

About Copart NASDAQ: CPRTCopart NASDAQ: CPRT is a global provider of online vehicle auction and remarketing services, focused primarily on the sale of salvage and clean-title vehicles. The company operates a technology-driven auction platform that connects sellers — including insurance companies, vehicle finance firms, rental car companies, dealerships and fleet owners — with a broad buyer base consisting of vehicle dismantlers, recyclers, rebuilders and retail buyers. Copart's business model centers on efficient vehicle disposition using digital bidding and logistics services to maximize recovery value for its clients.

Core services include hosting live and timed online auctions, vehicle listing and inspection support, title processing, and transportation and storage solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Copart Right Now?Before you consider Copart, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Copart wasn't on the list.

While Copart currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Key Takeaways Copart Q3 EPS rose 2.4% to 43 cents as revenues climbed 2.1% to $1.24 billion.CPRT lifted gross margin to 46.3% as higher ASPs offset lower unit volumes. Copart international revenues jumped 14.1% on higher units sold and stronger fee momentum. Copart, Inc. (CPRT - Free Report) delivered third-quarter fiscal 2026 earnings of 43 cents per share, which rose 2.4% year over year and beat the Zacks Consensus Estimate of 41 cents by 4.9%. Quarterly revenues rose 2.1% year over year to $1.24 billion and topped the Zacks Consensus Estimate of $1.21 billion by 2.4%.

The quarter reflected resilient pricing amid softer volumes. Average selling prices (ASPs) increased 4.6% while unit volumes declined 2.4%, helping lift revenues despite pressure in global insurance units, which fell 2.7%.

CPRT’s Revenue Mix Improves as Vehicle Sales GrowService revenues remained the primary engine, rising 2.1% year over year to $1.06 billion. Vehicle sales advanced 2.3% to $181 million, adding a modest but helpful tailwind to consolidated growth.

The continued expansion in average selling prices across channels more than offset lower volumes. The company reported low-single-digit growth in global assignment volumes, even as global inventory declined by 2% from the prior year.

Copart’s Margins Expand Despite Higher Facility CostsGross profit increased 3.7% to $572.6 million, and gross margin expanded 71 basis points to 46.3%. Cost of vehicle sales declined 5.6% to $160.3 million, helping offset higher facility operations expenses, which rose 2.5% to $450.3 million.

Operating leverage was mixed below the gross line. General and administrative expenses increased 7.2% to $93.7 million, and total operating expenses rose 1.7% to $772.8 million. Even with that uptick, operating income grew 2.8% to $464.3 million, reflecting the benefit of stronger gross profit and continued operating discipline.

CPRT’s U.S. Business is Steady as Units FallThe United States segment posted total revenues of $1 billion, down 0.4% year over year, as higher revenue per unit was offset by lower volumes. The U.S. insurance volumes decreased 4.2%, consistent with softer claims activity tied to consumer insurance affordability dynamics.

Beyond insurance, the company noted encouraging momentum across parts of its diversified seller base. Dealer Services and powersports units increased 1%, BluCar commercial consignment expanded more than 4%, and combined fleet and finance seller volume grew at a double-digit pace, partly offset by higher repair activity among rental customers.

Copart’s International Segment Drives Incremental GrowthInternational revenues climbed 14.1% year over year to $234.2 million, supported by a 5.9% increase in total units sold and solid fee momentum. Service revenues in the international segment increased as revenue per unit benefited from strong average selling price gains, with insurance ASPs up 8.4% and noninsurance ASPs up 16.7%.

Profitability also strengthened overseas. International operating income rose to $73.8 million, translating to a 31.5% operating margin.

CPRT’s Cash Position Strengthens as Buybacks ContinueAs of April 30, 2026, Copart had cash, cash equivalents and restricted cash of $3.35 billion, up from $2.78 billion as of July 31, 2025. Liquidity was approximately $5.5 billion, including cash, equivalents and held-to-maturity securities, providing flexibility for investment and capital returns.

Cash flow reflected heavy capital allocation activity. Net cash provided by operating activities for the first nine months of fiscal 2026 was $1.25 billion, while purchases of property and equipment totaled $258.6 million. The company also repurchased $1.63 billion of common stock during the first nine months, underscoring an ongoing commitment to returning capital alongside investments in land, facilities and technology.

Copart’s Operating Drivers Centered on Returns and ServicesThe auction returns remain a key lever in the insurance ecosystem. In the quarter, U.S. insurance average selling prices increased 4.1%, supported by a broad and diversified buyer base, including international demand that the company said represents a meaningful share of U.S. auction proceeds.

The company continues the expansion of value-added services that can lift revenue per unit over time. Title processing offerings and logistics initiatives, including its domestic long-haul delivery product, were framed as both revenue opportunities and tools to reduce friction for buyers and sellers across the platform.

CPRT currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Releases From Auto SpaceMobileye Global Inc. (MBLY - Free Report) reported first-quarter 2026 results on April 23. It posted earnings of 12 cents per share, beating the Zacks Consensus Estimate of 8 cents by 58.52%. The bottom line rose 50% year over year, driven by higher shipments of EyeQ system-on-chip. The company posted revenues of $558 million, which beat the Zacks Consensus Estimate of $520 million by 7.36% and increased 27.4% year over year.

Operating cash flow was $75 million, reflecting the company’s ability to convert its ADAS scale into cash generation.

Mobileye also approved a share buyback program of up to $250 million. By the end of the first quarter, MBLY had $1.21 billion in cash, after spending $591 million (net of cash received) on the Mentee Robotics acquisition.

Gentex Corporation (GNTX - Free Report) reported first-quarter 2026 results on April 24. It posted adjusted earnings of 48 cents per share, which beat the Zacks Consensus Estimate of 44 cents by 8.28%. The figure increased 11.6% from 43 cents a year ago. Net sales came in at $675 million, topping the consensus mark of $647 million by 4.36%. Revenues rose 17.1% from $577 million in the year-ago quarter, aided by contributions from VOXX and a richer mix of advanced features.

Liquidity improved during the quarter. As of March 31, 2026, GNTX’s cash and cash equivalents were $164.8 million compared with $145.6 million as of Dec. 31, 2025. Short-term investments increased to $10.3 million from $5.4 million.

PACCAR Inc. (PCAR - Free Report) reported first-quarter 2026 results on April 28. It reported earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.13 by 1.8%. The bottom line decreased 21.2% from $1.46 in the year-ago quarter. Consolidated revenues (including trucks and financial services) were $6.78 billion, down from $7.44 billion in the corresponding quarter of 2025. The decline reflected lower industry volumes.

On the balance sheet, cash and marketable securities were $8.60 billion as of March 31, 2026, compared with $9.25 billion as of Dec. 31, 2025, while stockholders’ equity increased to $19.76 billion from $19.26 billion over the same span.

Lululemon Athletica (LULU) lowered FY26 guidance, citing ongoing profit and margin pressures despite a Q1 top- and bottom-line beat. LULU's Q2 revenue and EPS guidance both fell short of consensus, with management adopting a more conservative outlook amid lower-quality online traffic.

NewPeak Metals Ltd (ASX:NPM, OTC:NPMFF, FRA:NPM) has completed more than 1,800 metres of diamond drilling at its Las Opeñas Gold Project in Argentina, with...

Stocks are under pressure in premarket trading Friday, putting the S&P 500 in danger of snapping a nine-week winning streak; chip stocks are extending yesterday's losses as the AI trade stumbles after a recent rally; the May jobs report is expected to show that U.S. employers added roles for the third straight month; S&P Global said it is not making changes to its rules for new additions to stock indexes, which would keep SpaceX, Anthropic and OpenAI from being quickly added after their mega-IPOs; and Lululemon shares are tumbling after the apparel maker cut its full-year outlook. Here's what you need to know today.

Lululemon Athletica LULU shares fell sharply on Friday after the athletic apparel retailer lowered its annual profit outlook and issued weaker-than-expected sales guidance, deepening investor concerns about the pace of its turnaround efforts.

The stock dropped nearly 9% in early trading after the company projected flat to slightly lower revenue for the full year.

The company also warned that profitability would come under pressure as it increases promotions and works to revive demand in its core North American market.

The selloff adds to a difficult period for the Vancouver-based company, whose shares have lost nearly 65% of their value over the past 12 months as competition intensifies and product momentum weakens.

For the full year, Lululemon now expects revenue to range between $11 billion and $11.15 billion, representing a decline of 1% to flat growth.

The previous forecast had called for revenue growth of 2% to 4%.

The company also reduced its earnings-per-share guidance to between $10.95 and $11.15, down from its earlier outlook of $12.10 to $12.30.

The outlook for the current quarter was equally disappointing.

Lululemon forecast revenue of $2.45 billion to $2.48 billion and earnings of $1.76 to $1.81 per share, both well below analyst expectations compiled by FactSet.

The weaker projections come as the company ramps up discounting, refreshes its product assortment, and adjusts marketing strategies while also dealing with margin pressure from higher tariffs.

Chief Financial Officer and Interim Co-Chief Executive Meghan Frank acknowledged that recent negative publicity has hurt the brand's performance.

The company's image "took a beating in the media and on social channels recently," Frank told analysts, adding that weaker consumer traffic had weighed on sales.

Lululemon also admitted that some recent product introductions failed to generate the momentum management had anticipated.

A newly launched yoga apparel collection received positive customer feedback but failed to drive broader purchasing activity across the company's product portfolio.

"These styles were met with good guest response, but so far, the campaign hasn't had the expected halo effect on other areas of our assortment," Frank said.

Despite the setbacks, she stressed that management was moving quickly to address the issues.

"I want to emphasize that we are not sitting still and we are moving with urgency to make the necessary adjustments to re-accelerate momentum, particularly in North America," Frank said during a call with analysts.

The guidance cut arrives during a period of significant leadership change for the retailer.

Lululemon is currently being run by Frank and President and Chief Commercial Officer André Maestrini following the departure of former CEO Calvin McDonald earlier this year.

Former Nike executive Heidi O'Neill is scheduled to take over as chief executive in September, but analysts caution that meaningful improvements may take time.

The company recently settled a long-running dispute with founder Chip Wilson, who had publicly criticized management and launched a proxy fight aimed at reshaping the board.

Under the agreement, Wilson will nominate two directors, while the company will appoint a third board member with apparel and brand expertise.

In exchange, Wilson agreed to suspend his campaign and refrain from public criticism for 18 months.

Wall Street analysts reacted cautiously to the earnings update, warning that competitive pressures remain intense.

Barclays analysts said Lululemon had entered a "trap" phase where business fundamentals are deteriorating amid fierce competition and weakening pricing power.

Jefferies analyst Randal Konik said worsening sales trends in the United States remain a major concern and pointed to declining store productivity as a key risk.

William Blair analysts noted that negative social media commentary and disappointing product launches are likely to result in weaker comparable sales and heavier markdown activity through the second quarter.

The firm also warned that 2027 could become another transition year given the timing of the leadership changes.

Oppenheimer maintained confidence in the strength of the brand but expressed concern about the company's near-term prospects.

Analysts Brian Nagel and Andrew Chasanoff said they remain constructive on "the underlying prowess of the Lululemon brand" but warned that the company risks stagnation as smaller competitors continue to gain ground in the athleisure market.

While O'Neill's appointment is viewed positively, her non-compete agreement means she cannot begin until September, potentially delaying major product initiatives until well into 2028, according to the firm.

For investors, the latest results suggest Lululemon's turnaround may take longer than expected, with leadership changes, product execution challenges, and intensifying competition all standing in the way of a quick recovery.

Lululemon’s NASDAQ: LULU Q1 results reveal a fundamental truth that will impact its share price long into the future. While still a growing company, offering value to investors, the brand just isn’t as cool as it used to be, and that’s a hard-to-overcome headwind.

lululemon athletica Today

LULU

lululemon athletica

$119.34 -2.50 (-2.05%)

As of 12:42 PM Eastern

This is a fair market value price provided by Massive. Learn more.

52-Week Range$109.36▼

$252.24P/E Ratio9.63

Price Target$154.26

Lululemon is no longer the status symbol it once was, and other brands are taking center stage. The question today is whether this stock will rebound in 2026 or continue declining, and the stage is set for another substantial decline to bring its price to 10-year lows.

Get lululemon athletica alerts:

The technical risk is significant. LULU’s post-release price action trimmed more than 10% off the stock price overnight in aftermarket trading, putting it at a multiyear low and below a critical support target. At this level, selling can gain momentum, and the downside risk is substantial. The clearest target for strong support lies near a trading range dating back to 2018. Moving to the high end of that trading range would equate to a 28% decline in the stock price; a move to the low end would add another 35% to the decline.

Analysts Slash Targets, Lead LULU Shares to Fresh LowsPrice weakness was underpinned by the analyst reaction to the report. While some expressed optimism about Lululemon’s brand power and long-term prospects, none issued a price target increase or upgrades. 100% of the initial updates from analysts included a price target reduction, with new updates averaging a target of $115, well below the previous consensus.

lululemon athletica Stock Forecast Today12-Month Stock Price Forecast:
$154.26
28.28% Upside

Reduce
Based on 33 Analyst Ratings

Current Price$120.25High Forecast$500.00Average Forecast$154.26Low Forecast$88.00lululemon athletica Stock Forecast Details

The critical takeaway is that analysts' trends are souring, leading to levels below the critical support target, and are unlikely to change soon. UBS, specifically, stated this is not a buying opportunity because risks remain unchanged. In fact, the weak Q1 results suggest the risks have only increased.

Institutional headwinds are among the risks. The trailing-12-month activity reflects accumulation, but the balance is slim, and many quarters are net negative in dollar terms. More importantly, institutions, which own an 85% stake, were selling ahead of the release.

The risk is that this group continues unloading shares, potentially accelerating their activity should indexes and their corresponding funds start reducing exposure. Holdings are broad-based but centered in ETFs and mutual funds.

Lulu is a component of the S&P 500 and could be removed due to loss of market capitalization, sustained weakness, or reduced relevance, all of which pose risks in 2026.

Short selling is another risk investors should consider. With blood in the water, short sellers may pile into this trade, and activity has been heating up. Late May data show short interest up for the third month, at a 10-month high. At 5.28%, the current short interest level isn’t a serious threat, but it shows increased activity and could rise quickly, given the lowered guidance and risks presented in the earnings release.

Lululemon Outperforms, But Low Bar and Guidance Offset the StrengthLululemon had a good quarter at face value. The $2.47 billion in revenue was up 4.2% and outperformed MarketBeat’s consensus by approximately 150 basis points. The bad news is that the bar was set low; 100% of analysts had reduced their target during the quarter and were expecting much worse, and this was the slowest Q1 take in a long time. Additionally, weakness in the core U.S. market is to blame and is unlikely to end soon.

Margin was another concern: with new product launches failing to ignite sales, the company is leaning into markdowns to clear inventory, which is hurting both revenue growth and profitability. So, though the $1.69 in adjusted earnings per share was better than the consensus forecast, it was offset by a low bar and weak guidance, which is the operative factor on the stock price this summer.

Lululemon’s guidance was beyond weak. The company issued initial Q2 and full-year updates significantly below consensus. The high end of the revenue and earnings ranges were double-digit percentage points below expectation and still could be overly optimistic. As it stands, there is no reason to be hopeful, and that will be reflected in the stock price.

The trigger investors need to be prepared for is an alteration in the share buyback trend. As it stands, Lululemon is aggressively reducing its count, having bought back approximately 4.4% of shares since last Q1. The balance sheet remains healthy, and cash flow is positive, but margins are already contracting, and revenue is forecast to follow suit, so capital returns are at risk. The catalyst to watch is the international expansion. It provides a path to growth at scale that can sustain cash flow and share buybacks over time.

Should You Invest $1,000 in lululemon athletica Right Now?Before you consider lululemon athletica, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and lululemon athletica wasn't on the list.

While lululemon athletica currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights.

We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of lululemon athletica inc. (NASDAQ: LULU) breached their fiduciary duties to shareholders.

If you currently own lululemon stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Lululemon turned in solid results but lowered its guidance as trends weakened during the quarter. The company's new CEO won't take over until September.

Key Takeaways LULU lowered its 2026 outlook despite Q1 revenues of $2.47B and EPS of $1.69 topping estimates.LULU cited negative media commentary and uneven product launches as key slowdown drivers.LULU posted 30% China revenue growth and plans further expansion, including entry into India. lululemon athletica inc. (LULU - Free Report) used its first-quarter 2026 earnings call to address a sharp moderation in sales trends that emerged late in the quarter, prompting a reduction to its full-year outlook.

Management pointed to brand-related disruptions and uneven product launch performance as key factors behind the slowdown, while outlining actions aimed at restoring momentum in North America and sustaining international growth.

LULU Cuts Outlook as Trends WeakenInterim Co-CEO and CFO Meghan Frank said the company entered the year with encouraging signs but encountered softer demand toward the end of the first quarter and into the second quarter.

The company posted first-quarter revenues of $2.47 billion, representing a 4% year-over-year increase, while earnings per share came in at $1.69. Both metrics surpassed the Zacks Consensus Estimate, with revenues exceeding expectations of $2.43 billion and earnings topping the forecast of $1.67 by approximately 1.3%.

lululemon athletica inc. Price, Consensus and EPS Surprise

Despite the quarterly beat, management lowered its 2026 outlook. Revenues are now expected between $11 billion and $11.15 billion, representing flat to down 1% growth from 2025, while earnings per share are projected between $10.95 and $11.15.

Lululemon Identifies Two Key HeadwindsFrank said the company’s analysis pointed to two primary drivers behind the recent slowdown.

First, spikes in negative media and social-media commentary weighed on traffic and overall sales performance. Management said the issue affected both the United States and China and became most visible in late April and early May.

Second, several recent product launches failed to generate the expected level of consumer response. While some new introductions performed well, the company acknowledged that not all product initiatives delivered the anticipated lift across the broader assortment.

LULU Focuses on Product Speed and InnovationManagement emphasized that product remains the centerpiece of its recovery strategy.

Frank highlighted strong guest response to updates within key franchises such as Fast & Free, Swiftly and Metal Vent, as well as newer offerings including Daydrift and Define. However, the company said its recent “new look of yoga” campaign did not translate into the broader sales acceleration it expected.

To improve responsiveness, lululemon is increasing chase production volume by 20% this year and shortening product development timelines. Management said development cycles have already been reduced to roughly 15 to 16 months from as much as 24 months and are targeted to reach 12 to 14 months over time.

International Markets Remain a Bright SpotWhile North America continues to face pressure, international operations remain a major source of growth.

China Mainland revenues increased 30% in the quarter, while management maintained its expectation for approximately 20% growth in the market for the full year. Interim Co-CEO and President Andre Maestrini said guest engagement remains strong through community events and brand activations despite temporary disruption from negative commentary.

Outside China, revenues in the Rest of World segment rose 13%. Maestrini highlighted continued opportunities across APAC and EMEA and noted that lululemon recently opened its first store in Greece and plans to enter India later this year through a franchise partnership.

Analysts Press Management on Product and TrafficSeveral analysts focused their questions on product execution and the abrupt decline in traffic.

A Raymond James analyst asked whether recent product challenges could spread internationally. Maestrini responded that international markets continue to benefit from strong demand for core franchises while also supporting a broader mix of new products.

A JPMorgan analyst sought clarification on the North American slowdown. Frank said February and March performed well before trends weakened in late April. She emphasized that management is not assuming significant benefits from ongoing corrective actions in its current guidance, leaving room for improvement if initiatives gain traction.

Lululemon Steps Up Brand InvestmentsManagement outlined a broader effort to rebuild brand momentum.

The company plans to increase marketing spending, expand community-based events and pursue more product collaborations and experiential activations. Upcoming initiatives include the return of the SeaWheeze Half Marathon in Vancouver and expanded yoga-focused programming across key markets.

Executives also highlighted operational initiatives aimed at improving efficiency, including supply-chain optimization, procurement savings and greater use of AI-powered systems across the enterprise.

Management Sees Long-Term Opportunity Despite ChallengesThroughout the call, executives maintained that the recent slowdown does not alter the company's long-term growth opportunity.

Management repeatedly emphasized discipline, product innovation, guest engagement and international expansion as the core pillars of its strategy. The company also noted that inventory units were down approximately 4% year over year, giving it flexibility to chase successful products more aggressively.

While near-term visibility remains constrained by softer North American demand, management signaled confidence that ongoing operational and brand-building initiatives can support a return to stronger performance over time.

What the Zacks Signals IndicateLULU currently carries a Zacks Rank #3 (Hold), indicating a more balanced outlook based on earnings estimate revisions. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The stock also holds Value Score A, Growth Score B, Momentum Score A and VGM Score A. Under the Zacks framework, strong Style Scores can help identify attractive value, growth and momentum characteristics, particularly when paired with favorable Zacks Ranks. Investors should note that the Zacks Rank can change following future estimate revisions as analysts reassess the company’s outlook after the latest results.

Have you evaluated the performance of Lululemon's (LULU - Free Report) international operations during the quarter that concluded in April 2026? Considering the extensive worldwide presence of this athletic apparel maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.

In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place great importance on grasping the extent of a company's dependence on international markets, as it sheds light on the firm's earnings stability, its skill in leveraging various economic cycles and its broad growth potential.

Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.

In our recent assessment of LULU's quarterly performance, we discovered notable trends in its overseas revenue sections, which are typically modeled and scrutinized by Wall Street analysts.

The company's total revenue for the quarter amounted to $2.47 billion, showing rise of 4.3%. We will now explore the breakdown of LULU's overseas revenue to assess the impact of its international operations.

Exploring LULU's International Revenue PatternsOf the total revenue, $283.34 million came from Canada during the last fiscal quarter, accounting for 11.5%. This represented a surprise of +1.13% as analysts had expected the region to contribute $280.19 million to the total revenue. In comparison, the region contributed $477.47 million, or 13.1%, and $292.82 million, or 12.4%, to total revenue in the previous and year-ago quarters, respectively.

China Mainland generated $478.4 million in revenues for the company in the last quarter, constituting 19.4% of the total. This represented a surprise of +2.32% compared to the $467.55 million projected by Wall Street analysts. Comparatively, in the previous quarter, China Mainland accounted for $528.44 million (14.5%), and in the year-ago quarter, it contributed $368.1 million (15.5%) to the total revenue.

Hong Kong SAR, Taiwan, and Macau SAR accounted for 2.1% of the company's total revenue during the quarter, translating to $51.41 million. Revenues from this region represented a surprise of +1.04%, with Wall Street analysts collectively expecting $50.88 million. When compared to the preceding quarter and the same quarter in the previous year, Hong Kong SAR, Taiwan, and Macau SAR contributed $60.88 million (1.7%) and $44.1 million (1.9%) to the total revenue, respectively.

During the quarter, Other geographic areas contributed $320.59 million in revenue, making up 13% of the total revenue. When compared to the consensus estimate of $326.47 million, this meant a surprise of -1.8%. Looking back, Other geographic areas contributed $370.6 million, or 10.2%, in the previous quarter, and $283.9 million, or 12%, in the same quarter of the previous year.

Revenue Projections for Overseas MarketsThe current fiscal quarter's total revenue for Lululemon, as projected by Wall Street analysts, is expected to reach $2.47 billion, reflecting a decline of 2.3% from the same quarter last year. The breakdown of this revenue by foreign region is as follows: Canada is anticipated to contribute 12.8% or $315.01 million, China Mainland 19.5% or $480.36 millionHong Kong SAR, Taiwan, and Macau SAR 2.3% or $56.74 million and Other geographic areas 15.8% or $388.68 million.

For the full year, a total revenue of $11.26 billion is expected for the company, reflecting an increase of 1.4% from the year before. The revenues from Canada, China Mainland, Hong Kong SAR, Taiwan, and Macau SAR and Other geographic areas are expected to make up 12.6%, 18.8%, 2.1%, and 11.9% of this total, corresponding to $1.41 billion, $2.12 billion, $236.72 million, and $1.34 billion, respectively.

Key TakeawaysRelying on global markets for revenues presents both prospects and challenges for Lululemon. Therefore, scrutinizing its international revenue trends is key to effectively forecasting the company's future outlook.

In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.

Here at Zacks, we put a great deal of emphasis on a company's changing earnings outlook, as empirical research has shown that's a powerful force driving a stock's near-term price performance. Quite naturally, the correlation is positive here -- an upward revision in earnings estimates drives the stock price higher.

Our proprietary stock rating tool, the Zacks Rank, with its externally validated exceptional track record, harnesses the power of earnings estimate revisions to serve as a dependable measure for anticipating the short-term price trends of stocks.

At the moment, Lululemon has a Zacks Rank #4 (Sell), signifying that it may underperform the overall market trend in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

A Look at Lululemon's Recent Stock Price PerformanceThe stock has declined by 7% over the past month compared to the 0.2% increase of the Zacks S&P 500 composite. Meanwhile, the Zacks Consumer Discretionary sector, which includes Lululemon,has decreased 1.2% during this time frame. Over the past three months, the company's shares have experienced a loss of 26.5% relative to the S&P 500's 10.2% increase. Throughout this period, the sector overall has witnessed a 5.3% decrease.

Apparel company Lululemon Athletica (LULU 2.19%) recently reported earnings, and they did little to calm investor fears about the business. Disappointing top-line numbers and a troubling forecast have resulted in the stock hitting new lows.

The company has been struggling for a while and has announced a new CEO. A turnaround won't be easy, but if it's successful, the stock could be poised to deliver some fantastic returns for investors who take a chance on the company. While there is some considerable risk with the stock, has it become so cheap that it's worth buying right now?

Image source: Getty Images.

Lululemon reported minimal growth last quarter Lululemon reported its latest earnings numbers last week, and the results simply weren't good, and definitely not what you'd expect from a top growth stock, which is what Lululemon used to be.

Revenue of $2.5 billion for the period ending May 3 was up 4% year over year, but was just 2% on a constant-dollar basis. And its comparable sales were only up by 1%, which is a more useful indicator when assessing its organic growth. With such minimal growth, it's little wonder why investors have been dumping the stock this year. What was even more worrisome, however, was that its net income fell by 38% to $195 million.

In addition, the company slashed its guidance for earnings per share by over $1, now projecting a range of $10.95 to $11.15 for the full fiscal year (which ends around February).

Today's Change

(

-2.19

%) $

-2.67

Current Price

$

119.17

The stock is cheap, but is it really just a value trap at this point? Lululemon's value has declined by more than 60% in the past five years, with its market cap now around $14 billion. Its price-to-earnings multiple of 10 looks incredibly low given that the average stock on the S&P 500 trades at a multiple of around 26.

That's a steep discount, but it begs the question of whether it's simply a value trap. The business isn't doing well, profits are down, and its ability to return to growth is by no means a certainty, particularly at a time when there's rising competition and consumers are more sensitive to price.

New CEO Heidi O'Neill has a strong pedigree, with decades of experience at Nike, but a turnaround for Lululemon won't be easy. Unless you have a high tolerance for risk and a whole lot of patience, you may be better off avoiding Lululemon's stock because, while it may seem cheap, there's no guarantee that it can't go lower. It's still a highly risky buy at this point.

-

BISMARCK, N.D.--(BUSINESS WIRE)--Knife River Corporation (NYSE: KNF) announced today that it has acquired the assets of Donaldson Brothers Ready Mix Inc., an aggregates-based ready-mix supplier in western Montana. This is Knife River’s third acquisition in its Mountain Segment in 2026.

Donaldson is a leading supplier of aggregates and ready-mix in the growing Bitterroot Valley, south of Missoula. In addition to three aggregates sources that provide the business with over 30 years of supply, Donaldson operates a ready-mix plant and manufactures precast concrete products.

Last month, Knife River acquired Morgan Asphalt Inc., based in Salt Lake City, Utah. In January, Knife River acquired the assets of Sparrow Enterprises Inc., in Helena, Mont.

“These three acquisitions in the Mountain Segment support our strategy of targeting aggregates-based, vertically integrated opportunities in mid-size, higher-growth markets,” said Knife River President and CEO Brian Gray. “The Donaldson assets provide strategic aggregate reserves in western Montana while establishing a foothold in a new market. Montana is growing, and we are now in an even better position to support that growth.”

About Knife River

Knife River Corporation, a member of the S&P MidCap 400 index, mines aggregates and markets crushed stone, sand, gravel and related construction materials, including ready-mix concrete, asphalt and other value-added products. Knife River also performs vertically integrated contracting services, specializing in publicly funded DOT projects and private projects across the industrial, commercial and residential space. For more information about the company, visit www.kniferiver.com.

Forward-Looking Statement

The information in this release includes certain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements contained in this release, including, but not limited to, statements about the growth potential in Montana, aggregate reserves and strategic expansion, are expressed in good faith and are believed by Knife River to have a reasonable basis. Nonetheless, actual results may differ materially from the projected results expressed in the forward-looking statements. There can be no assurance that the actual results or developments anticipated by Knife River will be realized or, even if substantially realized, that they will have the expected consequences to or effects on Knife River or its business or operations. For a discussion of important factors that could cause actual results to differ materially from those expressed in the forward-looking statements, refer to Item 1A-Risk Factors in Knife River’s Form 10-K. All forward-looking statements in this release are expressly qualified by such cautionary statements and by reference to the underlying assumptions. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Knife River does not undertake to update forward-looking statements, whether as a result of new information, future events or otherwise.

More News From Knife River Corporation

Back to Newsroom